Indicate the presence of numerical data in the abstract (whether numerical data plays a key role in medical records), solely using the information from the abstract.

Abstract: Developmental changes and sexual differences in the lactotrope population were studied with a reverse hemolytic plaque assay for detection and measurement of PRL secretion from individual cells in conjunction with PRL immunocytochemistry (ICC). Pituitary glands from both sexes at different ages were monodispersed with 0.1% trypsin. Freshly dispersed cells were incubated in Cunningham chambers for measurement of the fraction of plaque-forming cells and the size of plaques formed, or attached to glass slides for measurement of the fraction of cells staining for PRL by ICC. The percentage of plaque-forming cells in both sexes gradually increased with age from about 5% of the total anterior pituitary cell population at 5 days of age to the adult levels of about 54% in the females at proestrus and about 37% in the males. Sexual differences in the percentage of plaque-forming cells were consistently seen at 40 days of age and thereafter. The mean size of plaques in both sexes also increased with age from about 1,100 microns 2 at 5 days of age to a peak level of about 15,600 microns 2 in the females at proestrus and about 6,700 microns 2 in the males at 60 days of age; then fell to the adult levels of about 5,500 microns 2 in the females at proestrus and about 3,200 microns 2 in males. Sexual differences first appeared at 40 days of age and were estrogen-dependent. The results from ICC closely matched those from the plaque assay, except at 5 days of age and in the adult males. At 5 days, the fraction of cells staining for PRL was twice that of cells forming plaques. In adult male rats there were about 47% immunostained PRL cells but only about 39% plaque-forming cells. This difference, however, disappeared after estrogen treatment. These results demonstrate that sexual differences in the lactotrope population develop around puberty in rats and appear to be estrogen dependent.
Question: Does the abstract contain any numerical data?
Yes

Abstract: A patient with a mobile schwannoma of the cauda equina is described. There was considerable discrepancy between the localization of the tumor at myelography and the findings at both initial surgery and repeat myelography, confirmed by definitive surgery. Such mobility is rare, but should be kept in mind when surgery is performed for a tumor of the cauda equina.
Question: Does the abstract contain any numerical data?
No

Abstract: Studies in patients on dialysis have shown that aluminum (Al) accumulation in bone plays a major role in the pathogenesis of osteomalacia. It has been suggested that deferoxamine (DFO) may be beneficial in the treatment of aluminum-induced osteomalacia. The present studies were performed in four groups of uremic rats to determine if DFO and/or discontinuation of Al administration have an effect on bone histomorphometry and blood chemistries. The groups were: 1) uremic control 2) aluminum (0.75 to 1.0 mg/rat i.p., five times a week for twelve weeks): 3) aluminum + DFO, after twelve weeks Al was discontinued and the rats received DFO (75 mg/rat two times a week for nine weeks); 4) aluminum + time, after twelve weeks Al was discontinued and the rats were sacrificed after nine weeks. High levels of Al in serum and bone and low levels of PTH were seen in rats receiving Al. Bone histology revealed Al at the mineralization front, abnormal tetracycline uptake, and an increase in osteoid. DFO treatment did not significantly change the level of Al in bone, however both DFO treatment and discontinuation of Al reversed towards normal the above described lesions. In conclusion, these studies suggest that DFO and/or discontinuation of Al administration to rats with approximately 30% of renal function greatly improve aluminum-induced osteomalacia.
Question: Does the abstract contain any numerical data?
Yes